<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id><journal-title-group><journal-title>Clinical and Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">2001-1326</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5482791</article-id><article-id pub-id-type="publisher-id">151</article-id><article-id pub-id-type="doi">10.1186/s40169-017-0151-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>IFN&#x003b3;-producing CD4<sup>+</sup> T lymphocytes: the double-edged swords in tuberculosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kumar</surname><given-names>Pawan</given-names></name><address><email>pkscmm@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0498 924X</institution-id><institution-id institution-id-type="GRID">grid.10706.30</institution-id><institution>Special Centre for Molecular Medicine, </institution><institution>Jawaharlal Nehru University, </institution></institution-wrap>New Mehrauli Road, New Delhi, 110067 India </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>21</elocation-id><history><date date-type="received"><day>30</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">IFN&#x003b3;-producing CD4<sup>+</sup> T cells (IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells) are the key orchestrators of protective immunity against <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>). Primarily, these cells act by enabling <italic>Mtb</italic>-infected macrophages to enforce phagosome-lysosome fusion, produce reactive nitrogen intermediates (RNIs), and activate autophagy pathways. However, TB is a heterogeneous disease and a host of clinical and experimental findings has also implicated IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis. High frequency of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells is the most invariable feature of the active disease. Active TB patients mount a heightened IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response to mycobacterial antigens and demonstrate an IFN&#x003b3;-inducible transcriptomic signature. IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells have also been shown to mediate TB-associated immune reconstitution inflammatory syndrome (TB&#x02013;IRIS) observed in a subset of antiretroviral therapy (ART)-treated HIV- and <italic>Mtb</italic>-coinfected people. The pathological face of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during mycobacterial infection is further uncovered by studies in the animal model of TB&#x02013;IRIS and in <italic>Mtb</italic>-infected PD-1<sup>&#x02212;/&#x02212;</sup> mice. This manuscript encompasses the evidence supporting the dual role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection and sheds light on immune mechanisms involved in protection versus pathogenesis.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Tuberculosis</kwd><kwd>Protection</kwd><kwd>Pathogenesis</kwd><kwd>IFN-gamma</kwd><kwd>CD4<sup>+</sup> T cell</kwd><kwd>TB&#x02013;IRIS</kwd><kwd>Macrophage</kwd><kwd>Neutrophil</kwd><kwd>Necrosis</kwd><kwd>Matrix metalloproteinase</kwd><kwd>Granuloma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par10">Tuberculosis (TB) continues to be one of the major causes of morbidity and mortality worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>), the causative agent of TB, mainly resides in host macrophages and modulates their cellular physiology to support its own growth and duplication. Although macrophages are armed with a battery of antimicrobial mechanisms, elimination of the intracellular bacilli from these cells is largely dependent on activation signals arising from CD4<sup>+</sup> T lymphocytes [<xref ref-type="bibr" rid="CR2">2</xref>]. A key role in CD4<sup>+</sup> T cell-mediated macrophage activation can be attributed to IFN&#x003b3;, which helps in <italic>Mtb</italic> clearance by inducing iNOS expression and enforcing phagosome-lysosome fusion [<xref ref-type="bibr" rid="CR2">2</xref>]. T<sub>H</sub>1-polarized CD4<sup>+</sup> T cells are the main source of IFN&#x003b3; during mycobacterial infections. Significantly enhanced susceptibility to TB in people suffering from HIV/AIDS or inherited IFN&#x003b3; deficiencies underlines the critical role of IFN&#x003b3;-producing CD4<sup>+</sup> T cells (IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells) in host resistance to <italic>Mtb</italic> [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par11">The protective role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells against <italic>Mtb</italic>, however, is one side of the story. With advancements in TB immunobiology, a host of studies has emerged to show that IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells are directly or indirectly involved in TB pathogenesis. It has been observed that active TB patients mount a heightened T<sub>H</sub>1 type of CD4<sup>+</sup> T cell responses against <italic>Mtb</italic> antigens [<xref ref-type="bibr" rid="CR3">3</xref>]. T<sub>H</sub>1 type of CD4<sup>+</sup> T cell response can also be observed in latently infected people, but its aggravation commonly precedes the reactivation of latent TB into the active disease [<xref ref-type="bibr" rid="CR3">3</xref>]. Similar aggravation of T<sub>H</sub>1 type of antimycobacterial immunity also occurs in TB&#x02013;associated immune reconstitution inflammatory syndrome (TB&#x02013;IRIS) observed in a subset of antiretroviral therapy (ART)-treated HIV- and <italic>Mtb</italic>-coinfected people [<xref ref-type="bibr" rid="CR4">4</xref>]. Studies in both human patients and the&#x000a0;animal models have attributed the pathogenesis of TB&#x02013;IRIS to hyperactive IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par12">The present manuscript elaborates on the clinical and experimental findings demonstrating the protective versus the pathological role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection. It further sheds light on the underlying mechanisms of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-mediated protection against TB and TB pathogenesis. Besides broadening individual&#x02019;s perspective of TB immunobiology, this manuscript will prompt the TB vaccinologists to retrospect their strategies to combat this age-old disease.</p></sec><sec id="Sec2"><title>Protective role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells against <italic>Mtb</italic></title><p id="Par13">Nearly one-third of the world&#x02019;s population is infected with <italic>Mtb</italic> [<xref ref-type="bibr" rid="CR6">6</xref>]. However, most of the latently infected people never develop active TB, demonstrating the competence of their immune system to contain the bacilli [<xref ref-type="bibr" rid="CR2">2</xref>]. Both human and animal studies have established that IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells are the key mediators of protective immunity against <italic>Mtb</italic>. It has been shown that mice deficient in IFN&#x003b3; are unable to control low-dose <italic>Mtb</italic> infection and succumb to the progressive disease [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. As CD4<sup>+</sup> T lymphocytes are the most important source of IFN&#x003b3; during mycobacterial infection, animals deficient in CD4<sup>+</sup> T cells have also been found to be susceptible to low-dose <italic>Mtb</italic> infection. Other lymphocyte subsets such as CD8<sup>+</sup> T cells, natural killer (NK) cells, CD1-restricted T cells and &#x003b3;&#x003b4; T cells also secrete IFN&#x003b3; in response to <italic>Mtb</italic> infection, but they are unable to compensate for the lack of CD4<sup>+</sup> T lymphocytes as a source of this cytokine [<xref ref-type="bibr" rid="CR2">2</xref>]. Mounting of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses relies on IL-12 secretion by antigen-presenting cells. Consistently, animals deficient in IL-12 are also unable to control <italic>Mtb</italic> infection and die of the progressive disease [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par14">The importance of IL-12/IFN&#x003b3; axis in protection against human TB is illustrated by people having mutations in the genes encoding these cytokines [<xref ref-type="bibr" rid="CR2">2</xref>]. Such people exhibit Mendelian susceptibility to mycobacterial disease (MSMD) and are predisposed to progressive infection with BCG and environmental non-tuberculous mycobacteria [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Similarly, lack of IFN&#x003b3; receptor 1 (IFN&#x003b3;R1) has been shown to cause fatal lepromatoid BCG infection and disseminated non-tuberculous mycobacterial disease [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Since IFN&#x003b3; production depends on IL-12, deficiency in IL-12 receptor &#x003b2;1 (IL-12R&#x003b2;1) has also been shown to result in severe primary TB in the affected individuals [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par15">One of the most important evidence supporting the protective role of CD4<sup>+</sup> T cells against human TB is provided by people suffering from HIV/AIDS. Infection with HIV leads to selective deletion of CD4<sup>+</sup> T lymphocytes, which in turn results in the significantly enhanced susceptibility to TB [<xref ref-type="bibr" rid="CR17">17</xref>]. Owing to the unrestricted growth of the bacilli, TB frequently affects extrapulmonary sites in HIV/AIDS patients, and can also occur in disseminated form in the severe cases. Similar to the case of HIV/AIDS, idiopathic CD4<sup>+</sup> T cell lymphocytopenia has also been shown to increase TB susceptibility and its associated mortality [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec3"><title>Mechanisms of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-mediated protection against <italic>Mtb</italic></title><p id="Par16">Despite the long known role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in protection against <italic>Mtb</italic>, its underlying mechanisms are not completely understood. Studies aimed at elucidating the mechanisms of IFN&#x003b3;-mediated protection against <italic>Mtb</italic> have largely focused on its effect on the infected macrophages. These studies have revealed that IFN&#x003b3;-activated macrophages eliminate the intracellular bacilli primarily by: (i) producing reactive nitrogen intermediates (RNIs), (ii) enforcing phagosome-lysosome fusion, and (iii) activating the autophagy pathway.</p><p id="Par17">Nitric oxide and other RNIs help in the clearance of the intracellular bacilli by inflicting oxidative damage on to them [<xref ref-type="bibr" rid="CR20">20</xref>]. <italic>Mtb</italic>-infected macrophages, however, did not produce copious amounts of RNIs in the absence of activating signals. IFN&#x003b3; promotes iNOS expression in <italic>Mtb</italic>-infected macrophages which catabolizes <sc>l</sc>-arginine into nitric oxide (NO), which in turn is used as the substrate to generate other RNIs [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The indispensable role of RNIs in protection against TB is demonstrated by the enhanced susceptibility of iNOS<sup>&#x02212;/&#x02212;</sup> mice to <italic>Mtb</italic> [<xref ref-type="bibr" rid="CR22">22</xref>]. Besides having a direct effect on intracellular <italic>Mtb</italic>, RNIs can also reduce the bacillary load by inducing apoptotic cell death in infected macrophages [<xref ref-type="bibr" rid="CR21">21</xref>]. Apoptosis of infected macrophages is a protective response and is associated with diminished <italic>Mtb</italic> survival. As <italic>Mtb</italic>-containing apoptotic bodies are readily phagocytosed by dendritic cells, it also augments <italic>Mtb</italic>-specific immunity [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par18">One of the important strategies evolved by <italic>Mtb</italic> and other pathogenic mycobacteria to survive within infected macrophages is to inhibit phagosome maturation. By excluding vacuolar H<sup>+</sup>-ATPase, pathogenic mycobacteria inhibit phagosome acidification and escape the degradative action of lysosomal acid hydrolases [<xref ref-type="bibr" rid="CR24">24</xref>]. Studies with <italic>Mtb</italic>-infected macrophages have shown that IFN&#x003b3; signalling can activate these cells to enforce phagosome maturation and eliminate the intracellular bacilli [<xref ref-type="bibr" rid="CR25">25</xref>]. Transcription of pH-responsive genes in IFN&#x003b3;-activated macrophages and attenuation of the acid-susceptible <italic>Mtb</italic> strains in the infected animals shows that IFN&#x003b3; signalling enables the infected macrophages to overcome phagosomal maturation block both in vitro and in vivo [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par19">Autophagy was initially described as a cell survival mechanism during starvation. A plethora of recent studies has demonstrated that autophagy also plays a key role in protection against the intracellular pathogens including <italic>Mtb</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. Antimycobacterial effects of autophagy have been attributed to enhanced killing of mycobacteria within the infected cells and reduced inflammation in the affected tissues [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The genetic link between autophagy, inflammatory conditions, and TB susceptibility provides an important support to the role of anti-inflammatory and bactericidal properties of autophagy in protection against human TB [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. IFN&#x003b3; is a potent autophagy inducer in the <italic>Mtb</italic>-infected macrophages and produces the cellular effects similar to that of starvation [<xref ref-type="bibr" rid="CR33">33</xref>]. Studies by Matsuzawa et al. have shown that IFN&#x003b3;-induced macrophage autophagy is mediated by JAK1/2, PI3K, and p38MAPK and is independent of STAT1 [<xref ref-type="bibr" rid="CR34">34</xref>]. Interestingly, T<sub>H</sub>2 cytokines IL-4 and IL-13 have been shown to hamper IFN&#x003b3;-induced autophagy in macrophages, suggesting an alternate mechanism for their deleterious effects on anti-<italic>Mtb</italic> immunity [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec4"><title>Pathological role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection</title><p id="Par20">Despite their protective role against <italic>Mtb</italic>, IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells have been implicated in TB pathogenesis by a number of studies. This section presents the clinical and experimental findings demonstrating the involvement of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis. Notably, the pathological character of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells is predominantly manifested in a subset of <italic>Mtb</italic>-infected immunocompetent adults and TB&#x02013;IRIS patients, wherein these cells exhibit excessive responsiveness to mycobacterial antigens [<xref ref-type="bibr" rid="CR3">3</xref>]. In immunocompetent adults, active TB develops from the reactivation of latent infection and primarily affects lung tissue. An overly intense IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response is the most important immunological parameter distinguishing the active disease from latent infection in these people [<xref ref-type="bibr" rid="CR27">27</xref>]. On the contrary, the incompetence of host immune system to contain the bacilli is responsible for TB pathogenesis in young children and immunodeficient people [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par21">Classical evidence supporting the pathological role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection is provided by tuberculin skin testing (TST)&#x02014;a diagnostic test to examine <italic>Mtb</italic> exposure. TST involves the intradermal injection of purified <italic>Mtb</italic> antigens, followed by monitoring for the delayed-type hypersensitivity (DTH) reaction seen as local skin induration. As DTH is mediated by T<sub>H</sub>1-polarized CD4<sup>+</sup> T cells, a larger area of skin induration in TB patients demonstrates a strong association between IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells and the active disease [<xref ref-type="bibr" rid="CR36">36</xref>]. In latently infected people, the area of skin induration has been found to correlate with the future risk of active TB [<xref ref-type="bibr" rid="CR37">37</xref>]. Therefore, an intense tuberculin reaction is considered as more serious and indicates the likelihood of the concomitant active disease or its future risk [<xref ref-type="bibr" rid="CR38">38</xref>]. However, it should be noted that lack of reactivity or anergy to <italic>Mtb</italic> antigens does not predict the resistance to active TB. As it signifies the lack of T<sub>H</sub>1 response to mycobacteria, anergy to mycobacterial antigens is associated with enhanced risk of morbidity and mortality in the infected people [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par22">Studies aimed at characterizing the host immune response during <italic>Mtb</italic> infection further suggest the involvement of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis. These studies have shown the heightened levels of IFN&#x003b3; in lung tissue, broncho-alveolar lavage (BAL) fluid, pleural effusion, and lymph nodes of active TB patient [<xref ref-type="bibr" rid="CR2">2</xref>]. BAL fluid IFN&#x003b3; levels in active TB patients have been found to directly correlate with the disease severity and subsided with its successful treatment [<xref ref-type="bibr" rid="CR40">40</xref>]. These findings are supported by transcriptomic analysis of whole blood cells from TB patients and healthy controls by Berry et al. [<xref ref-type="bibr" rid="CR41">41</xref>]. The authors have&#x000a0;observed an enhanced transcription of IFN&#x003b3;-inducible genes in active TB patients, compared with latently infected people and healthy controls. Consistent with enhanced IFN&#x003b3; levels, increased frequency of IFN&#x003b3;-producing CD4<sup>+</sup> T cells during active TB has been reported by several studies [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>]. Although most of these studies have shown the polyfunctionality of CD4<sup>+</sup> T cells in active TB patients, the specific role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis is evident from animal studies.</p><p id="Par23">Unequivocal support for the pathological role of IFN&#x003b3;-producing CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection is provided by TB&#x02013;associated immune reconstitution inflammatory syndrome (TB&#x02013;IRIS). Affecting a subset of antiretroviral therapy (ART)-treated HIV- and <italic>Mtb</italic>-coinfected people, TB&#x02013;IRIS occurs in diverse manifestations and poses a major challenge in the clinical management of HIV in these people. Mechanistically, the&#x000a0;ART-mediated decline in the viral load allows for the rapid expansion of <italic>Mtb</italic>-specific CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. Both terminally-differentiated and effector memory CD4<sup>+</sup> T cells with specificity to <italic>Mtb</italic> antigens have been shown to expand in ART-treated HIV- and <italic>Mtb</italic>-coinfected people [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Exaggeration of antimycobacterial immunity (with CD4<sup>+</sup> T cell expansion) in the&#x000a0;ART-treated HIV- and <italic>Mtb</italic>-coinfected people is evidenced by their conversion from a &#x02018;negative&#x02019; TST status to a strongly &#x02018;positive&#x02019; one [<xref ref-type="bibr" rid="CR49">49</xref>]. Interestingly, ART-treated people who develop TB&#x02013;IRIS demonstrate a more strong T<sub>H</sub>1 type of CD4<sup>+</sup> T cell response to <italic>Mtb</italic> antigens, compared with those who do not experience this condition [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Evidently, immunological parameters in TB&#x02013;IRIS patients pint out an active participation of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis.</p><p id="Par24">Direct involvement of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB&#x02013;IRIS development is confirmed by a mouse model, wherein the human disease has been mimicked by adoptively transferring na&#x000ef;ve CD4<sup>+</sup> T cells into <italic>M. avium</italic>-infected, T cell-deficient (TCR&#x003b1;<sup>&#x02212;/&#x02212;</sup>) mice [<xref ref-type="bibr" rid="CR5">5</xref>]. It has been shown that adoptively transferred CD4<sup>+</sup> T lymphocytes rapidly acquired T<sub>H</sub>1 phenotype and led to the failure of lung function, wasting and eventual death of host animals. The authors have&#x000a0;further noted that ability of the donor lymphocytes to cause lung pathology was lost in IFN&#x003b3;-deficient CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR5">5</xref>]. Thus, both human and animal studies attribute the pathogenesis of TB&#x02013;IRIS to <italic>Mtb</italic>-specific IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells.</p><p id="Par25">Studies in PD-1<sup>&#x02212;/&#x02212;</sup> mice and a macaque model further confirm the direct involvement of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells in TB pathogenesis [<xref ref-type="bibr" rid="CR51">51</xref>]. PD-1 is present on T lymphocytes and its engagement by PD-L1 results in the negative regulation of T cell functions [<xref ref-type="bibr" rid="CR2">2</xref>]. As PD-L1 was found to be abundant in TB patients, researchers wondered over the outcome of PD-1 signalling during <italic>Mtb</italic> infection and examined it using knockout mouse strains [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Surprisingly, it was observed that instead of developing resistance to <italic>Mtb</italic>, PD-1<sup>&#x02212;/&#x02212;</sup> mice exhibited significantly enhanced susceptibility to mycobacterial infection. Further analysis of TB pathogenesis in PD-1<sup>&#x02212;/&#x02212;</sup> mice revealed that these animals mount an exaggerated IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response to the bacilli [<xref ref-type="bibr" rid="CR51">51</xref>]. Besides PD-1, CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> T regulatory (T<sub>reg</sub>) cells can also suppress the exaggerated IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response during mycobacterial infection [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. In macaque model of TB, higher frequency of T<sub>reg</sub> cells has been observed in the animals who would develop the latent infection, compared with those that would develop the active disease [<xref ref-type="bibr" rid="CR55">55</xref>]. These findings in PD-1<sup>&#x02212;/&#x02212;</sup> mice and the macaque model demonstrate that aggravated IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response is the key mediator of TB pathology and that its inhibition prevents the reactivation of latent infection into the active disease.</p><p id="Par26">It is evident from the above-discussed findings that protective versus pathological character of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells is defined by the degree of their responsiveness to <italic>Mtb</italic>. A hyperactive IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response to <italic>Mtb</italic> is pathological in nature and is frequently observed in adult TB patients. After initial exposure, most of the immunocompetent adults would contain <italic>Mtb</italic> infection without developing any disease symptom. This condition of asymptomatic <italic>Mtb</italic> infection, referred to as latent TB, represents the state of protection against the bacilli. Latent TB persists lifelong in most, but nearly 10% of the infected people who would develop active TB in their lifetime. As discussed above, reactivation of latent infection into the active disease can be attributed to aggravated anti-<italic>Mtb</italic> IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses. Similar aggravation of <italic>Mtb</italic>-specific IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses is to blame for TB&#x02013;IRIS development in a subset of HIV- and <italic>Mtb</italic>-coinfected people. In contrast to immunocompetent adults and TB&#x02013;IRIS patients, most&#x000a0;young children and immunodeficient people mount a hypoactive IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response to <italic>Mtb</italic>, which is inefficient in containing the bacilli. Therefore, <italic>Mtb</italic> infection in these people leads to primary TB, frequently affecting the extrapulmonary sites. The protective versus pathological role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection is summarized in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Protective versus pathological role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) infection. <italic>Mtb</italic> exposure in most&#x000a0;young children and immunodeficient people evokes a hypoactive IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response, which is inefficient in containing the bacilli. Therefore, <italic>Mtb</italic> infection in these people results in primary TB, frequently affecting the extrapulmonary sites. In contrast, most of the immunocompetent adults mount a balanced immune response to <italic>Mtb</italic> and contain it in the form of latent TB. With the course of time, IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response would aggravate in nearly 10% of latently infected people, leading to the development of active TB in them. Similar aggravation of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells is to blame for TB&#x02013;IRIS development in a subset of ART-treated, HIV- and <italic>Mtb</italic>-coinfected people</p></caption><graphic xlink:href="40169_2017_151_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec5"><title>Mechanisms of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-mediated TB pathogenesis</title><p id="Par27">Preferential expression of IFN&#x003b3;-inducible genes in neutrophils (and to some extent in monocytes) during active TB indicates the involvement of these cells in IFN&#x003b3;-mediated TB pathogenesis [<xref ref-type="bibr" rid="CR56">56</xref>]. Neutrophils are frequently infected by <italic>Mtb</italic> and are abundant at the site of active disease. Although these cells may help in the containment of the bacilli during the initial phase of infection, their involvement in TB pathogenesis is supported by a number of studies. It has been shown that the frequency of neutrophils at the site of active disease correlates with the disease severity [<xref ref-type="bibr" rid="CR57">57</xref>]. Higher neutrophil count (neutrophilia) is associated with low sputum conversion and poor TB prognosis [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Increased frequency of neutrophils at the affected site has also been demonstrated in susceptible mouse strains and their depletion from these animals resulted in the enhanced resistance to <italic>Mtb</italic> [<xref ref-type="bibr" rid="CR59">59</xref>]. Interestingly, IFN&#x003b3; has been shown to increase neutrophil lifespan which may potentially contribute to neutrophilia in the infected animals. Besides, the functional activity of neutrophils is also bolstered by IFN&#x003b3; [<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par28">
<italic>Mtb</italic>-infected neutrophils and macrophages are the potent producers of toxic molecules and matrix degrading enzymes, including elastases, myeloperoxidases, collagenases, and serine proteases. MMP-1 is a key collagenase up-regulated in TB patients and its enhanced levels have been shown to be associated with increased lung pathology in a transgenic mouse model [<xref ref-type="bibr" rid="CR61">61</xref>]. MMP-9, which has been implicated in the pathogenesis of many inflammatory diseases, is also abundant in active TB patients and is associated with poor prognosis of the disease [<xref ref-type="bibr" rid="CR62">62</xref>]. Interestingly, a heightened IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response has been shown to be associated with enhanced MMP production [<xref ref-type="bibr" rid="CR63">63</xref>]. Additionally, IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-activated neutrophils and macrophages produce copious amounts of reactive nitrogen intermediates (RNIs) and reactive oxygen species (ROS) which can damage the healthy tissue [<xref ref-type="bibr" rid="CR64">64</xref>]. A combined action of tissue-digesting enzymes and RNI/ROS can result in the dismantling of granuloma and progression of latent infection into active TB. Supporting this, higher neutrophil and inflammatory monocyte frequency, elevated serum nitrate levels, and enhanced MMP expression have been observed in the <italic>Mtb</italic>-infected animals, wherein pathology was mediated by IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par29">Necrotic cell death of neutrophils and macrophages also plays a key role in TB pathogenesis. The pathological role of necrotic cell death in TB has been demonstrated elegantly in the zebrafish model, wherein increased production of LXA4 (an inducer of necrosis) resulted in reduced host resistance to mycobacterial infection [<xref ref-type="bibr" rid="CR65">65</xref>]. These findings are relevant in human TB, for polymorphisms in <italic>Alox5</italic> and <italic>Ita4h</italic>, which regulate necrosis versus apoptosis, has been shown to define TB susceptibility [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Although IFN&#x003b3; promotes the necrosis in <italic>Mtb</italic>-infected macrophages [<xref ref-type="bibr" rid="CR67">67</xref>], its effect on neutrophils is not clear. It is probable that increased oxidative stress in the presence of IFN&#x003b3; could direct <italic>Mtb</italic>-infected neutrophils to the necrotic pathway.</p><p id="Par30">Another interesting mechanism of IFN&#x003b3;-mediated TB pathology has been demonstrated by Aly and co-workers [<xref ref-type="bibr" rid="CR68">68</xref>]. The authors have&#x000a0;demonstrated that by altering the balance between angiostatic and angiogenic mediators, IFN&#x003b3; disrupts the granuloma vascularization and leads to a hypoxic central core. Deprived of nutrients and oxygen supply, the core of granuloma necrotizes and undergoes caseation, resulting in the activation of latent infection into active TB [<xref ref-type="bibr" rid="CR68">68</xref>]. It is likely that the combined action of this and above-discussed mechanisms leads to IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-mediated TB pathogenesis in immunocompetent adults. The individual contribution of these mechanisms to the development of TB, however, awaits further analysis.</p></sec><sec id="Sec6"><title>Conclusion and future perspectives</title><p id="Par31">IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells are the key orchestrators of antimycobacterial immunity. However, with increasing recognition of TB as a heterogeneous disease [<xref ref-type="bibr" rid="CR2">2</xref>], IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells have also been implicated in TB pathogenesis. A more intense tuberculin reaction, which is driven by IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells, is frequently observed in TB patients, and its intensity in latently infected people indicates the future risk of the active disease in them [<xref ref-type="bibr" rid="CR27">27</xref>]. Active TB patients exhibit enhanced IFN&#x003b3; levels in different tissues which correlate with disease severity [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. In keeping with this, increased expression of IFN&#x003b3;-inducible genes has been observed in active TB patients, compared with latently infected people and healthy controls [<xref ref-type="bibr" rid="CR56">56</xref>]. The pathological face of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection is also obvious in TB&#x02013;IRIS patients and its animal model [<xref ref-type="bibr" rid="CR5">5</xref>]. Enhanced susceptibility of PD-1<sup>&#x02212;/&#x02212;</sup> mouse strains, which mount heightened IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses to <italic>Mtb</italic>, further support the pathological role of these cells during <italic>Mtb</italic> infection [<xref ref-type="bibr" rid="CR51">51</xref>]. Disrupted granuloma vascularization and/or neutrophil- and macrophage-mediated dismantling of granuloma architecture are important mechanisms of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell-mediated TB pathology.</p><p id="Par32">Owing to earlier studies demonstrating the protective role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection, vaccinologists had been aiming to boost IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell response as a strategy to TB immunoprophylaxis. Unfortunately, these strategies have failed to confer significant protection against human TB [<xref ref-type="bibr" rid="CR69">69</xref>]. Failure of rationally designed vaccines against human TB and the dual role of IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells during <italic>Mtb</italic> infection call for retrospection of our approach to TB vaccination. It is imperative that instead of boosting antimycobacterial immunity, researchers must attempt to dampen the IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cell responses in susceptible immunocompetent adults to prevent TB in them. Likely success of these approaches against human TB is suggested by animal studies.</p><p id="Par33">Conclusively, a significant volume of scientific data demonstrates that, besides conferring protection against <italic>Mtb</italic>, IFN&#x003b3;<sup>+</sup>CD4<sup>+</sup> T cells also play a key role in TB pathogenesis in immunocompetent adults. As adult TB represents the major burden of the disease, there is an urgency of legitimate efforts to evaluate the immune-dampening approaches in these patients. Not only these approaches can improve treatment outcome against the active disease, they are also likely to help in the effective management of drug-resistant TB, which has emerged as a major challenge for the clinicians.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>TB</term><def><p id="Par2">tuberculosis</p></def></def-item><def-item><term><italic>Mtb</italic></term><def><p id="Par3">
<italic>Mycobacterium tuberculosis</italic>
</p></def></def-item><def-item><term>IFN</term><def><p id="Par4">interferon</p></def></def-item><def-item><term>TB&#x02013;IRIS</term><def><p id="Par5">tuberculosis&#x02013;associated immune reconstitution inflammatory syndrome</p></def></def-item><def-item><term>PD-1</term><def><p id="Par6">programmed cell death protein-1</p></def></def-item><def-item><term>iNOS</term><def><p id="Par7">inducible nitric oxide synthase</p></def></def-item><def-item><term>RNIs</term><def><p id="Par8">reactive nitrogen intermediates</p></def></def-item><def-item><term>MMP</term><def><p id="Par9">matrix metalloproteinase</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>None.</p><sec id="FPar1"><title>Competing interests</title><p id="Par34">The author declares that he has no competing interests.</p></sec><sec id="FPar2"><title>Funding</title><p id="Par35">This work was not supported by funding from any agency.</p></sec><sec id="FPar3"><title>Publisher&#x02019;s Note</title><p id="Par36">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Global tuberculosis report 2016. 2016</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Garra</surname><given-names>A</given-names></name><name><surname>Redford</surname><given-names>PS</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Bloom</surname><given-names>CI</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Berry</surname><given-names>MP</given-names></name></person-group><article-title>The immune response in tuberculosis</article-title><source>Annu Rev Immunol</source><year>2013</year><volume>31</volume><fpage>475</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095939</pub-id><?supplied-pmid 23516984?><pub-id pub-id-type="pmid">23516984</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name></person-group><article-title>Adult pulmonary tuberculosis as a pathological manifestation of hyperactive antimycobacterial immune response</article-title><source>Clin Trans Med</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s40169-016-0119-0</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahnke</surname><given-names>YD</given-names></name><name><surname>Greenwald</surname><given-names>JH</given-names></name><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Roby</surname><given-names>G</given-names></name><name><surname>Antonelli</surname><given-names>LR</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selective expansion of polyfunctional pathogen-specific CD4+ T cells in HIV-1&#x02013;infected patients with immune reconstitution inflammatory syndrome</article-title><source>Blood</source><year>2012</year><volume>119</volume><issue>13</issue><fpage>3105</fpage><lpage>3112</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-09-380840</pub-id><?supplied-pmid 22219223?><pub-id pub-id-type="pmid">22219223</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Antonelli</surname><given-names>LR</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name><name><surname>White</surname><given-names>S</given-names></name><name><surname>Caspar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Th1-driven immune reconstitution disease in Mycobacterium avium&#x02013;infected mice</article-title><source>Blood</source><year>2010</year><volume>116</volume><issue>18</issue><fpage>3485</fpage><lpage>3493</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-05-286336</pub-id><?supplied-pmid 20656932?><pub-id pub-id-type="pmid">20656932</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dye</surname><given-names>C</given-names></name><name><surname>Scheele</surname><given-names>S</given-names></name><name><surname>Dolin</surname><given-names>P</given-names></name><name><surname>Pathania</surname><given-names>V</given-names></name><name><surname>Raviglione</surname><given-names>MC</given-names></name></person-group><article-title>Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country</article-title><source>JAMA</source><year>1999</year><volume>282</volume><issue>7</issue><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1001/jama.282.7.677</pub-id><?supplied-pmid 10517722?><pub-id pub-id-type="pmid">10517722</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Bloom</surname><given-names>BR</given-names></name></person-group><article-title>An essential role for interferon gamma in resistance to <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><issue>6</issue><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id><?supplied-pmid 7504064?><pub-id pub-id-type="pmid">7504064</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Griffin</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>D</given-names></name><name><surname>Orme</surname><given-names>I</given-names></name></person-group><article-title>Disseminated tuberculosis in interferon gamma gene-disrupted mice</article-title><source>J Exp Med</source><year>1993</year><volume>178</volume><issue>6</issue><fpage>2243</fpage><lpage>2247</lpage><pub-id pub-id-type="doi">10.1084/jem.178.6.2243</pub-id><?supplied-pmid 8245795?><pub-id pub-id-type="pmid">8245795</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>AM</given-names></name><name><surname>DiFazio</surname><given-names>R</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name></person-group><article-title>IFN-&#x003b3; from CD4 T cells is essential for host survival and enhances CD8 T cell function during <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>J Immunol</source><year>2013</year><volume>190</volume><issue>1</issue><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200061</pub-id><?supplied-pmid 23233724?><pub-id pub-id-type="pmid">23233724</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Magram</surname><given-names>J</given-names></name><name><surname>Ferrante</surname><given-names>J</given-names></name><name><surname>Orme</surname><given-names>IM</given-names></name></person-group><article-title>Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with <italic>Mycobacterium tuberculosis</italic></article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><issue>1</issue><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1084/jem.186.1.39</pub-id><?supplied-pmid 9206995?><pub-id pub-id-type="pmid">9206995</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name></person-group><article-title>Role of innate cytokines in mycobacterial infection</article-title><source>Mucosal Immunol</source><year>2011</year><volume>4</volume><issue>3</issue><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/mi.2011.13</pub-id><?supplied-pmid 21430655?><pub-id pub-id-type="pmid">21430655</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name></person-group><article-title>Genetic dissection of immunity to mycobacteria: the human model</article-title><source>Annu Rev Immunol</source><year>2002</year><volume>20</volume><issue>1</issue><fpage>581</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.20.081501.125851</pub-id><?supplied-pmid 11861613?><pub-id pub-id-type="pmid">11861613</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorman</surname><given-names>SE</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Lammas</surname><given-names>D</given-names></name><name><surname>Heyne</surname><given-names>K</given-names></name><name><surname>van Dissel</surname><given-names>JT</given-names></name><name><surname>Baretto</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical features of dominant and recessive interferon &#x003b3; receptor 1 deficiencies</article-title><source>Lancet</source><year>2004</year><volume>364</volume><issue>9451</issue><fpage>2113</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17552-1</pub-id><?supplied-pmid 15589309?><pub-id pub-id-type="pmid">15589309</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Lamhamedi-Cherradi</surname><given-names>S</given-names></name><name><surname>Altare</surname><given-names>F</given-names></name><name><surname>Fondan&#x000e8;che</surname><given-names>M-C</given-names></name><name><surname>Tuerlinckx</surname><given-names>D</given-names></name><name><surname>Blanche</surname><given-names>S</given-names></name><etal/></person-group><article-title>Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette&#x02013;Guerin infection and a sibling with clinical tuberculosis</article-title><source>J Clin Investig</source><year>1997</year><volume>100</volume><issue>11</issue><fpage>2658</fpage><pub-id pub-id-type="doi">10.1172/JCI119810</pub-id><?supplied-pmid 9389728?><pub-id pub-id-type="pmid">9389728</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boisson-Dupuis</surname><given-names>S</given-names></name><name><surname>El Baghdadi</surname><given-names>J</given-names></name><name><surname>Parvaneh</surname><given-names>N</given-names></name><name><surname>Bousfiha</surname><given-names>A</given-names></name><name><surname>Bustamante</surname><given-names>J</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><etal/></person-group><article-title>IL-12R&#x003b2;1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>4</issue><fpage>e18524</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0018524</pub-id><?supplied-pmid 21533230?><pub-id pub-id-type="pmid">21533230</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caragol</surname><given-names>I</given-names></name><name><surname>Raspall</surname><given-names>M</given-names></name><name><surname>Fieschi</surname><given-names>C</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><name><surname>Larrosa</surname><given-names>MN</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor &#x003b2;1 deficiency</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><issue>2</issue><fpage>302</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1086/375587</pub-id><?supplied-pmid 12856223?><pub-id pub-id-type="pmid">12856223</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corbett</surname><given-names>EL</given-names></name><name><surname>Watt</surname><given-names>CJ</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name><name><surname>Maher</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>BG</given-names></name><name><surname>Raviglione</surname><given-names>MC</given-names></name><etal/></person-group><article-title>The growing burden of tuberculosis: global trends and interactions with the HIV epidemic</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>9</issue><fpage>1009</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1001/archinte.163.9.1009</pub-id><?supplied-pmid 12742798?><pub-id pub-id-type="pmid">12742798</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>DS</given-names></name><name><surname>Esmadi</surname><given-names>M</given-names></name><name><surname>Steinmann</surname><given-names>WC</given-names></name></person-group><article-title>Idiopathic CD4 lymphocytopenia: spectrum of opportunistic infections, malignancies, and autoimmune diseases</article-title><source>Avicenna J Med</source><year>2013</year><volume>3</volume><issue>2</issue><fpage>37</fpage><pub-id pub-id-type="doi">10.4103/2231-0770.114121</pub-id><?supplied-pmid 23930241?><pub-id pub-id-type="pmid">23930241</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Socio</surname><given-names>GV</given-names></name><name><surname>Gerli</surname><given-names>R</given-names></name><name><surname>Menichetti</surname><given-names>F</given-names></name></person-group><article-title>Disseminated tuberculosis and idiopathic CD4+ T-lymphocytopenia</article-title><source>Clin Microbiol Infect</source><year>1999</year><volume>5</volume><issue>10</issue><fpage>653</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.1999.tb00426.x</pub-id><?supplied-pmid 11851700?><pub-id pub-id-type="pmid">11851700</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>FC</given-names></name></person-group><article-title>Antimicrobial reactive oxygen and nitrogen species: concepts and controversies</article-title><source>Nat Rev Microbiol</source><year>2004</year><volume>2</volume><issue>10</issue><fpage>820</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1004</pub-id><?supplied-pmid 15378046?><pub-id pub-id-type="pmid">15378046</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>S</given-names></name><name><surname>Schaible</surname><given-names>UE</given-names></name><name><surname>Schneider</surname><given-names>BE</given-names></name></person-group><article-title>Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>5</issue><fpage>e19105</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0019105</pub-id><?supplied-pmid 21559306?><pub-id pub-id-type="pmid">21559306</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMicking</surname><given-names>JD</given-names></name><name><surname>North</surname><given-names>RJ</given-names></name><name><surname>LaCourse</surname><given-names>R</given-names></name><name><surname>Mudgett</surname><given-names>JS</given-names></name><name><surname>Shah</surname><given-names>SK</given-names></name><name><surname>Nathan</surname><given-names>CF</given-names></name></person-group><article-title>Identification of nitric oxide synthase as a protective locus against tuberculosis</article-title><source>Proc Natl Acad Sci</source><year>1997</year><volume>94</volume><issue>10</issue><fpage>5243</fpage><lpage>5248</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.10.5243</pub-id><?supplied-pmid 9144222?><pub-id pub-id-type="pmid">9144222</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behar</surname><given-names>SM</given-names></name><name><surname>Martin</surname><given-names>CJ</given-names></name><name><surname>Nunes-Alves</surname><given-names>C</given-names></name><name><surname>Divangahi</surname><given-names>M</given-names></name><name><surname>Remold</surname><given-names>HG</given-names></name></person-group><article-title>Lipids, apoptosis, and cross-presentation: links in the chain of host defense against <italic>Mycobacterium tuberculosis</italic></article-title><source>Microbes Infect</source><year>2011</year><volume>13</volume><issue>8</issue><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2011.03.002</pub-id><?supplied-pmid 21458584?><pub-id pub-id-type="pmid">21458584</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>D</given-names></name><name><surname>Bach</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Hmama</surname><given-names>Z</given-names></name><name><surname>Av-Gay</surname><given-names>Y</given-names></name></person-group><article-title><italic>Mycobacterium tuberculosis</italic> protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+&#x02013;ATPase to inhibit phagosome acidification</article-title><source>Proc Natl Acad Sci</source><year>2011</year><volume>108</volume><issue>48</issue><fpage>19371</fpage><lpage>19376</lpage><pub-id pub-id-type="doi">10.1073/pnas.1109201108</pub-id><?supplied-pmid 22087003?><pub-id pub-id-type="pmid">22087003</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>JD</given-names></name><name><surname>Gomez</surname><given-names>JE</given-names></name></person-group><article-title>Life on the inside for <italic>Mycobacterium tuberculosis</italic></article-title><source>Nat Med</source><year>2003</year><volume>9</volume><issue>11</issue><fpage>1356</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1038/nm1103-1356</pub-id><?supplied-pmid 14595429?><pub-id pub-id-type="pmid">14595429</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrt</surname><given-names>S</given-names></name><name><surname>Schnappinger</surname><given-names>D</given-names></name></person-group><article-title>Mycobacterial survival strategies in the phagosome: defence against host stresses</article-title><source>Cell Microbiol</source><year>2009</year><volume>11</volume><issue>8</issue><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2009.01335.x</pub-id><?supplied-pmid 19438516?><pub-id pub-id-type="pmid">19438516</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>RJ</given-names></name><name><surname>Jung</surname><given-names>Y-J</given-names></name></person-group><article-title>Immunity to tuberculosis</article-title><source>Annu Rev Immunol</source><year>2004</year><volume>22</volume><fpage>599</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104635</pub-id><?supplied-pmid 15032590?><pub-id pub-id-type="pmid">15032590</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campoy</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>MI</given-names></name></person-group><article-title>Autophagy in intracellular bacterial infection. Biochimica et biophysica acta (BBA)-molecular</article-title><source>Cell Res</source><year>2009</year><volume>1793</volume><issue>9</issue><fpage>1465</fpage><lpage>1477</lpage></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Songane</surname><given-names>M</given-names></name><name><surname>Kleinnijenhuis</surname><given-names>J</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name></person-group><article-title>The role of autophagy in host defence against <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>Tuberculosis</source><year>2012</year><volume>92</volume><issue>5</issue><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2012.05.004</pub-id><?supplied-pmid 22683183?><pub-id pub-id-type="pmid">22683183</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo</surname><given-names>EF</given-names></name><name><surname>Dekonenko</surname><given-names>A</given-names></name><name><surname>Arko-Mensah</surname><given-names>J</given-names></name><name><surname>Mandell</surname><given-names>MA</given-names></name><name><surname>Dupont</surname><given-names>N</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation</article-title><source>Proc Natl Acad Sci</source><year>2012</year><volume>109</volume><issue>46</issue><fpage>E3168</fpage><lpage>E3176</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210500109</pub-id><?supplied-pmid 23093667?><pub-id pub-id-type="pmid">23093667</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deretic</surname><given-names>V</given-names></name></person-group><article-title>Autophagy in tuberculosis</article-title><source>Cold Spring Harb Perspect Med</source><year>2014</year><volume>4</volume><issue>11</issue><fpage>a018481</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a018481</pub-id><?supplied-pmid 25167980?><pub-id pub-id-type="pmid">25167980</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Mizushima</surname><given-names>N</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name></person-group><article-title>Autophagy in immunity and inflammation</article-title><source>Nature</source><year>2011</year><volume>469</volume><issue>7330</issue><fpage>323</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1038/nature09782</pub-id><?supplied-pmid 21248839?><pub-id pub-id-type="pmid">21248839</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rovetta</surname><given-names>AI</given-names></name><name><surname>Pena</surname><given-names>D</given-names></name><name><surname>Hern&#x000e1;ndez Del Pino</surname><given-names>RE</given-names></name><name><surname>Recalde</surname><given-names>GM</given-names></name><name><surname>Pellegrini</surname><given-names>J</given-names></name><name><surname>Bigi</surname><given-names>F</given-names></name><etal/></person-group><article-title>IFNG-mediated immune responses enhance autophagy against <italic>Mycobacterium tuberculosis</italic> antigens in patients with active tuberculosis</article-title><source>Autophagy</source><year>2014</year><volume>10</volume><issue>12</issue><fpage>2109</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.4161/15548627.2014.981791</pub-id><?supplied-pmid 25426782?><pub-id pub-id-type="pmid">25426782</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>B-H</given-names></name><name><surname>Shenoy</surname><given-names>AR</given-names></name><name><surname>Kamitani</surname><given-names>S</given-names></name><name><surname>Miyake</surname><given-names>M</given-names></name><name><surname>MacMicking</surname><given-names>JD</given-names></name></person-group><article-title>IFN-&#x003b3; elicits macrophage autophagy via the p38 MAPK signaling pathway</article-title><source>J Immunol</source><year>2012</year><volume>189</volume><issue>2</issue><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1102041</pub-id><?supplied-pmid 22675202?><pub-id pub-id-type="pmid">22675202</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>J</given-names></name><name><surname>De Haro</surname><given-names>SA</given-names></name><name><surname>Master</surname><given-names>SS</given-names></name><name><surname>Keane</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>EA</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name><etal/></person-group><article-title>T helper 2 cytokines inhibit autophagic control of intracellular <italic>Mycobacterium tuberculosis</italic></article-title><source>Immunity</source><year>2007</year><volume>27</volume><issue>3</issue><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.07.022</pub-id><?supplied-pmid 17892853?><pub-id pub-id-type="pmid">17892853</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>North</surname><given-names>RJ</given-names></name><name><surname>Jung</surname><given-names>Y-J</given-names></name></person-group><article-title>Immunity to tuberculosis</article-title><source>Annu Rev Immunol</source><year>2004</year><volume>22</volume><issue>1</issue><fpage>599</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104635</pub-id><?supplied-pmid 15032590?><pub-id pub-id-type="pmid">15032590</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comstock</surname><given-names>GW</given-names></name><name><surname>Livesay</surname><given-names>VT</given-names></name><name><surname>Woolpert</surname><given-names>SF</given-names></name></person-group><article-title>The prognosis of a positive tuberculin reaction in childhood and adolescence</article-title><source>Am J Epidemiol</source><year>1974</year><volume>99</volume><issue>2</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a121593</pub-id><?supplied-pmid 4810628?><pub-id pub-id-type="pmid">4810628</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>TM</given-names></name><name><surname>Demissie</surname><given-names>A</given-names></name><name><surname>Olobo</surname><given-names>J</given-names></name><name><surname>Wolday</surname><given-names>D</given-names></name><name><surname>Britton</surname><given-names>S</given-names></name><name><surname>Eguale</surname><given-names>T</given-names></name><etal/></person-group><article-title>Immune responses to the <italic>Mycobacterium tuberculosis</italic>-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients</article-title><source>J Clin Microbiol</source><year>2002</year><volume>40</volume><issue>2</issue><fpage>704</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1128/JCM.40.2.704-706.2002</pub-id><?supplied-pmid 11826002?><pub-id pub-id-type="pmid">11826002</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Hughes</surname><given-names>P</given-names></name><name><surname>Clancy</surname><given-names>L</given-names></name></person-group><article-title>Skin anergy and tuberculosis</article-title><source>Respir Med</source><year>1992</year><volume>86</volume><issue>6</issue><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/S0954-6111(96)80006-0</pub-id><?supplied-pmid 1470704?><pub-id pub-id-type="pmid">1470704</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Chiou</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Hsieh</surname><given-names>M</given-names></name><name><surname>Tsao</surname><given-names>K</given-names></name></person-group><article-title>Levels of interferon-&#x003b3; and interleukin-2 receptor-&#x003b1; for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis</article-title><source>Int J Tuberc Lung Dis</source><year>2002</year><volume>6</volume><issue>8</issue><fpage>720</fpage><lpage>727</lpage><?supplied-pmid 12150485?><pub-id pub-id-type="pmid">12150485</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name></person-group><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><year>2010</year><volume>466</volume><issue>7309</issue><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id><?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sester</surname><given-names>U</given-names></name><name><surname>Fousse</surname><given-names>M</given-names></name><name><surname>Dirks</surname><given-names>J</given-names></name><name><surname>Mack</surname><given-names>U</given-names></name><name><surname>Prasse</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><etal/></person-group><article-title>Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><issue>3</issue><fpage>e17813</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0017813</pub-id><?supplied-pmid 21423578?><pub-id pub-id-type="pmid">21423578</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>MT</given-names></name><name><surname>Torres</surname><given-names>M</given-names></name><name><surname>Nevels</surname><given-names>D</given-names></name><name><surname>Perez-Redondo</surname><given-names>CN</given-names></name><name><surname>Ellner</surname><given-names>JJ</given-names></name><name><surname>Sada</surname><given-names>E</given-names></name><etal/></person-group><article-title>Compartmentalized bronchoalveolar IFN-&#x003b3; and IL-12 response in human pulmonary tuberculosis</article-title><source>Tuberculosis</source><year>2009</year><volume>89</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2008.08.002</pub-id><?supplied-pmid 18848499?><pub-id pub-id-type="pmid">18848499</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Multifunctional CD4 T cell responses in patients with active tuberculosis</article-title><source>Sci Rep</source><year>2012</year><volume>2</volume><fpage>216</fpage><?supplied-pmid 22355730?><pub-id pub-id-type="pmid">22355730</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerosa</surname><given-names>F</given-names></name><name><surname>Nisii</surname><given-names>C</given-names></name><name><surname>Righetti</surname><given-names>S</given-names></name><name><surname>Micciolo</surname><given-names>R</given-names></name><name><surname>Marchesini</surname><given-names>M</given-names></name><name><surname>Cazzadori</surname><given-names>A</given-names></name><etal/></person-group><article-title>CD4+ T cell clones producing both interferon-&#x003b3; and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients</article-title><source>Clin Immunol</source><year>1999</year><volume>92</volume><issue>3</issue><fpage>224</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1006/clim.1999.4752</pub-id><?supplied-pmid 10479527?><pub-id pub-id-type="pmid">10479527</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgarit</surname><given-names>A</given-names></name><name><surname>Carcelain</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>V</given-names></name><name><surname>Lascoux</surname><given-names>C</given-names></name><name><surname>Delcey</surname><given-names>V</given-names></name><name><surname>Gicquel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients</article-title><source>Aids</source><year>2006</year><volume>20</volume><issue>2</issue><fpage>F1</fpage><lpage>F7</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000202648.18526.bf</pub-id><?supplied-pmid 16511406?><pub-id pub-id-type="pmid">16511406</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>JS</given-names></name><name><surname>Young</surname><given-names>JM</given-names></name><name><surname>Peterson</surname><given-names>KL</given-names></name><name><surname>Sanneh</surname><given-names>B</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name><name><surname>Rowland-Jones</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Polyfunctional CD4+ and CD8+ T cell responses to tuberculosis antigens in HIV-1&#x02013;infected patients before and after anti-retroviral treatment</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><issue>11</issue><fpage>6537</fpage><lpage>6544</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1000399</pub-id><?supplied-pmid 20435929?><pub-id pub-id-type="pmid">20435929</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Seldon</surname><given-names>R</given-names></name><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Rangaka</surname><given-names>MX</given-names></name><name><surname>Hanekom</surname><given-names>WA</given-names></name><name><surname>Maartens</surname><given-names>G</given-names></name><etal/></person-group><article-title>Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by <italic>Mycobacterium tuberculosis</italic></article-title><source>Am J Respir Crit Care Med</source><year>2009</year><volume>180</volume><issue>7</issue><fpage>674</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1164/rccm.200904-0568OC</pub-id><?supplied-pmid 19628776?><pub-id pub-id-type="pmid">19628776</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>M</given-names></name><name><surname>Ashkin</surname><given-names>D</given-names></name><name><surname>Hollender</surname><given-names>ES</given-names></name><name><surname>Pitchenik</surname><given-names>AE</given-names></name></person-group><article-title>Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><issue>1</issue><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.158.1.9712001</pub-id><?supplied-pmid 9655723?><pub-id pub-id-type="pmid">9655723</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Rangaka</surname><given-names>MX</given-names></name><name><surname>Skolimowska</surname><given-names>K</given-names></name><name><surname>Van Veen</surname><given-names>K</given-names></name><name><surname>Abrahams</surname><given-names>M</given-names></name><etal/></person-group><article-title>Type 1 helper T cells and FoxP3-positive T cells in HIV&#x02013;tuberculosis-associated immune reconstitution inflammatory syndrome</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><issue>10</issue><fpage>1083</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1164/rccm.200806-858OC</pub-id><?supplied-pmid 18755923?><pub-id pub-id-type="pmid">18755923</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>S</given-names></name><name><surname>Kauffman</surname><given-names>KD</given-names></name><name><surname>Sallin</surname><given-names>MA</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Ganusov</surname><given-names>VV</given-names></name><etal/></person-group><article-title>CD4 T cell-derived IFN-&#x003b3; plays a minimal role in control of pulmonary <italic>Mycobacterium tuberculosis</italic> infection and must be actively repressed by PD-1 to prevent lethal disease</article-title><source>PLoS Pathog</source><year>2016</year><volume>12</volume><issue>5</issue><fpage>e1005667</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005667</pub-id><?supplied-pmid 27244558?><pub-id pub-id-type="pmid">27244558</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>Bloch</surname><given-names>SA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>7</issue><fpage>1941</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1002/eji.201141421</pub-id><?supplied-pmid 21509782?><pub-id pub-id-type="pmid">21509782</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burl</surname><given-names>S</given-names></name><name><surname>Hill</surname><given-names>P</given-names></name><name><surname>Jeffries</surname><given-names>D</given-names></name><name><surname>Holland</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>A</given-names></name><name><surname>Lugos</surname><given-names>M</given-names></name><etal/></person-group><article-title>FOXP3 gene expression in a tuberculosis case contact study</article-title><source>Clin Exp Immunol</source><year>2007</year><volume>149</volume><issue>1</issue><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03399.x</pub-id><?supplied-pmid 17465993?><pub-id pub-id-type="pmid">17465993</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro-Rodrigues</surname><given-names>R</given-names></name><name><surname>Resende Co</surname><given-names>T</given-names></name><name><surname>Rojas</surname><given-names>R</given-names></name><name><surname>Toossi</surname><given-names>Z</given-names></name><name><surname>Dietze</surname><given-names>R</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><etal/></person-group><article-title>A role for CD4+ CD25+ T cells in regulation of the immune response during human tuberculosis</article-title><source>Clin Exp Immunol</source><year>2006</year><volume>144</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03027.x</pub-id><?supplied-pmid 16542361?><pub-id pub-id-type="pmid">16542361</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>AM</given-names></name><name><surname>Mattila</surname><given-names>JT</given-names></name><name><surname>Bigbee</surname><given-names>CL</given-names></name><name><surname>Bongers</surname><given-names>KS</given-names></name><name><surname>Lin</surname><given-names>PL</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name></person-group><article-title>CD4+ regulatory T cells in a cynomolgus macaque model of <italic>Mycobacterium tuberculosis</italic> infection</article-title><source>J Infect Dis</source><year>2010</year><volume>202</volume><issue>4</issue><fpage>533</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1086/654896</pub-id><?supplied-pmid 20617900?><pub-id pub-id-type="pmid">20617900</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><etal/></person-group><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><year>2010</year><volume>466</volume><issue>7309</issue><fpage>7973</fpage><lpage>7977</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>DM</given-names></name><name><surname>Redford</surname><given-names>PS</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>O&#x02019;Garra</surname><given-names>A</given-names></name><name><surname>Martineau</surname><given-names>AR</given-names></name></person-group><article-title>Neutrophils in tuberculosis: friend or foe?</article-title><source>Trends Immunol</source><year>2012</year><volume>33</volume><issue>1</issue><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.it.2011.10.003</pub-id><?supplied-pmid 22094048?><pub-id pub-id-type="pmid">22094048</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PF</given-names></name><name><surname>Leedom</surname><given-names>JM</given-names></name><name><surname>Chan</surname><given-names>LS</given-names></name><name><surname>Wong</surname><given-names>SF</given-names></name><name><surname>Shah</surname><given-names>J</given-names></name><name><surname>Vachon</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Predictors of short-term prognosis in patients with pulmonary tuberculosis</article-title><source>J Infect Dis</source><year>1988</year><volume>158</volume><issue>2</issue><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1093/infdis/158.2.366</pub-id><?supplied-pmid 3403993?><pub-id pub-id-type="pmid">3403993</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeremeev</surname><given-names>V</given-names></name><name><surname>Linge</surname><given-names>I</given-names></name><name><surname>Kondratieva</surname><given-names>T</given-names></name><name><surname>Apt</surname><given-names>A</given-names></name></person-group><article-title>Neutrophils exacerbate tuberculosis infection in genetically susceptible mice</article-title><source>Tuberculosis</source><year>2015</year><volume>95</volume><issue>4</issue><fpage>447</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2015.03.007</pub-id><?supplied-pmid 25935122?><pub-id pub-id-type="pmid">25935122</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>TN</given-names></name><name><surname>Beaman</surname><given-names>BL</given-names></name></person-group><article-title>Interferon-&#x003b3; activation of polymorphonuclear neutrophil function</article-title><source>Immunology</source><year>2004</year><volume>112</volume><issue>1</issue><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.01849.x</pub-id><?supplied-pmid 15096178?><pub-id pub-id-type="pmid">15096178</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P</given-names></name><name><surname>Shiomi</surname><given-names>T</given-names></name><name><surname>Breen</surname><given-names>R</given-names></name><name><surname>Nuttall</surname><given-names>RK</given-names></name><name><surname>Ugarte-Gil</surname><given-names>CA</given-names></name><name><surname>Walker</surname><given-names>NF</given-names></name><etal/></person-group><article-title>MMP-1 drives immunopathology in human tuberculosis and transgenic mice</article-title><source>J Clin Investig</source><year>2011</year><volume>121</volume><issue>5</issue><fpage>1827</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1172/JCI45666</pub-id><?supplied-pmid 21519144?><pub-id pub-id-type="pmid">21519144</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Elkington PT, Ugarte-Gil CA, Friedland JS. Matrix metalloproteinases in tuberculosis. Eur Respiratory Soc; 2011</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadokera</surname><given-names>R</given-names></name><name><surname>Meintjes</surname><given-names>GA</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Skolimowska</surname><given-names>KH</given-names></name><name><surname>Walker</surname><given-names>N</given-names></name><name><surname>Friedland</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome</article-title><source>Eur J Immunol</source><year>2014</year><volume>44</volume><issue>1</issue><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1002/eji.201343593</pub-id><?supplied-pmid 24136296?><pub-id pub-id-type="pmid">24136296</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisenreich</surname><given-names>W</given-names></name><name><surname>Heesemann</surname><given-names>J</given-names></name><name><surname>Rudel</surname><given-names>T</given-names></name><name><surname>Goebel</surname><given-names>W</given-names></name></person-group><article-title>Metabolic host responses to infection by intracellular bacterial pathogens</article-title><source>Front Cell Infect Microbiol</source><year>2013</year><volume>3</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2013.00024</pub-id><?supplied-pmid 23847769?><pub-id pub-id-type="pmid">23847769</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>DM</given-names></name><name><surname>Vary</surname><given-names>JC</given-names></name><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>Walsh</surname><given-names>GS</given-names></name><name><surname>Dunstan</surname><given-names>SJ</given-names></name><name><surname>Bang</surname><given-names>ND</given-names></name><etal/></person-group><article-title>The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans</article-title><source>Cell</source><year>2010</year><volume>140</volume><issue>5</issue><fpage>717</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.013</pub-id><?supplied-pmid 20211140?><pub-id pub-id-type="pmid">20211140</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herb</surname><given-names>F</given-names></name><name><surname>Thye</surname><given-names>T</given-names></name><name><surname>Niemann</surname><given-names>S</given-names></name><name><surname>Browne</surname><given-names>EN</given-names></name><name><surname>Chinbuah</surname><given-names>MA</given-names></name><name><surname>Gyapong</surname><given-names>J</given-names></name><etal/></person-group><article-title>ALOX5 variants associated with susceptibility to human pulmonary tuberculosis</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><issue>7</issue><fpage>1052</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm378</pub-id><?supplied-pmid 18174194?><pub-id pub-id-type="pmid">18174194</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>K-W</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names></name></person-group><article-title><italic>Mycobacterium tuberculosis</italic> exploits human interferon &#x003b3; to stimulate macrophage extracellular trap formation and necrosis</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><issue>1</issue><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit097</pub-id><?supplied-pmid 23475311?><pub-id pub-id-type="pmid">23475311</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aly</surname><given-names>S</given-names></name><name><surname>Laskay</surname><given-names>T</given-names></name><name><surname>Mages</surname><given-names>J</given-names></name><name><surname>Malzan</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>R</given-names></name><name><surname>Ehlers</surname><given-names>S</given-names></name></person-group><article-title>Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis</article-title><source>J Pathol</source><year>2007</year><volume>212</volume><issue>3</issue><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1002/path.2185</pub-id><?supplied-pmid 17534845?><pub-id pub-id-type="pmid">17534845</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tameris</surname><given-names>MD</given-names></name><name><surname>Hatherill</surname><given-names>M</given-names></name><name><surname>Landry</surname><given-names>BS</given-names></name><name><surname>Scriba</surname><given-names>TJ</given-names></name><name><surname>Snowden</surname><given-names>MA</given-names></name><name><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial</article-title><source>Lancet</source><year>2013</year><volume>381</volume><issue>9871</issue><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60177-4</pub-id><?supplied-pmid 23391465?><pub-id pub-id-type="pmid">23391465</pub-id></element-citation></ref></ref-list></back></article>